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1. W with ACS who undergo coronary angiography have similar rates of STEMI,
NSTEMI, & biomarker release despite differences in baseline characteristics.
2. Evidence based medical therapy is similar except W are less likely to receive lipid low-
ering therapy than M (62% vs. 69% p<0.03)
3. We observed an apparent gender bias in revascularization favoring more PCI/CABG in
M.
4. Treatment bias against W with ACS receiving less revascularization was not due to
gender but rather to differences in severity of epicardial coronary obstruction.
1097-97 Safety of Stress Testing Following an Acute Coronary 
Syndrome
Juhana Karha, Christopher P. Cannon, Sabina A. Murphy, Peter M. DiBattiste, C. Michael 
Gibson, Eugene Braunwald, Brigham and Women's Hospital, Boston, MA
Background: The safety of stress testing within 72 hours following an acute coronary
syndrome has not been established.We hypothesized that performance of a stress test
within 48 to 72 hours after unstable angina (UA) or non-ST segment elevation myocardial
infarction (NSTEMI) would be safe. Methods: Patients (n=1,106) were drawn from the
conservative arm of the TACTICS/TIMI 18 trial. In TACTICS, 2,220 patients with UA/
NSTEMI were treated with aspirin, heparin, and tirofiban, and randomized to an early
invasive strategy or to a conservative strategy in which cardiac catheterization was per-
formed only if the patient had objective evidence of recurrent ischemia or an abnormal
stress test performed within 48 to 72 hours. Results: Of the 847 patients undergoing
stress testing, 494 underwent an exercise treadmill test (mean ± s.d. duration: 7.6 ± 3.2
min), and 353 underwent a pharmacologic stress test with adenosine (n=122), persan-
tine (n=152), or dobutamine (n=79). Per protocol, patients who developed spontaneous
recurrent ischemia prior to stress testing underwent a cardiac catheterization instead,
and a total of 259 patients in the conservative arm did not undergo a stress test. Mortality
at 30 days was 0.94% (8/847) among the patients who underwent a stress test. One of
the deaths occurred on the day of stress testing (mortality = 0.12%). Both of the patients
who died within 24 hours of stress testing had an elevated admission troponin, and one
also had transient ST segment elevation on the admission ECG. Only one patient suf-
fered an MI on the day of stress testing. Conclusions: In patients with UA/NSTEMI
treated with aspirin, heparin, and tirofiban, performance of an exercise or a pharmaco-
logic stress test is safe within 48 to 72 hours after admission.
1097-98 Early Continuous ST Monitoring Identifies Acute 
Coronary Syndrome Patients at High Risk of Death and 
Myocardial Infarction Despite Contemporary Treatment
Andrew T. Yan, Raymond Yan, Mary Tan, David H. Fitchett, Marc Cohen, Paul W. 
Armstrong, Anatoly Langer, Shaun G. Goodman, Canadian Heart Research Centre, 
Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada
Background: Previous small studies suggest continuous ST segment (Holter) monitor-
ing early after presentation can identify high risk patients with acute coronary syndromes
(ACS). However, it is unclear whether this technique remains useful in the contemporary
era of anti-thrombotic therapies.
Methods: In 2 randomized clinical trials comparing enoxaparin with unfractionated hep-
arin ± eptifibatide (INTERACT and ESSENCE ECG substudy), 853 patients with non-ST
elevation ACS underwent early continuous 96 hr Holter monitoring analyzed by an auto-
mated algorithm and reviewed by cardiologists blinded to clinical data. Outcomes at 30
days were independently adjudicated. We examined the prognostic value of Holter-
detected ischemia (HI; >0.1 mV ST deviation >1 min duration).
Results: Of the 853 patients enrolled, 261 (30.6%) had HI (see Table). 
After adjusting for other prognosticators including cardiac biomarker status, HI remained 
a strong predictor of death/MI [OR 3.5 (1.9-6.4), P<0.001] and all-cause mortality [OR 
4.3 (1.6-11.7), P=0.004] at 30 days. In multivariable analysis, renal dysfunction and ST 
deviation were independently associated with HI, while enoxaparin treatment significantly 
reduced the incidence of HI [OR 0.41 (0.28-0.60), P<0.001].
Conclusion: HI is a powerful independent predictor of mortality and MI among ACS 
patients treated in the modern era. This simple tool provides incremental prognostic 
value over the conventional risk stratification of non-ST elevation ACS patients.
1097-99 Racial Differences in Utilization of Primary Prevention 
Strategies and Cardiac Catheterization Following First 
Myocardial Infarction
Jon H. Mojares, Michael P. Hudson, Michelle Jankowski, Keisha R. Sandberg, Henry E. 
Kim, Henry Ford Heart and Vascular Institute, Detroit, MI
Background: Primary prevention strategies such as aspirin, ACE inhibitors and lipid low-
ering drugs may reduce the incidence of myocardial infarction (MI) in patients without
known coronary heart disease. We assessed the hypothesis that racial differences exist
in the implementation of primary prevention strategies.
Methods: In 1571 patients presenting between 1997-2001 with first acute MI and no
prior angina, MI or revascularization, we investigated the presence of racial differences in
the use of primary prevention.
Results: African American (AA) versus Caucasian patients had higher rates of diabetes
and hypertension with lower rates of hyperlipidemia (see table below). Rates of aspirin,
beta blocker, and lipid lowering drug use did not significantly differ according to race;
however, AA patients were more likely to receive ACE inhibitors prior to MI and less likely
to undergo post-MI catheterization.
Conclusions: Minimal differences exist in the use of MI primary prevention strategies
between Caucasian and AA patients. Following first MI, however, AA patients are less
likely to undergo aggressive evaluation with cardiac catheterization and revasculariza-
tion.
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1098-77 TIMI, PURSUIT and GRACE Risk Scores in Acute 
Coronary Syndromes: Comparison and Interaction With 
Myocardial Revascularization
Pedro Araujo Goncalves, Jorge Ferreira, Carlos Aguiar, Marisa Trabulo, Ricardo Seabra-
Gomes, Hospital de Santa Cruz, Carnaxide, Portugal
Background: Regarding prognosis, patients with a non-ST elevation acute coronary syn-
drome (ACS) are a very heterogeneous population, with varying risks of early and long-
term adverse events. Early risk stratification at admission seems to be essential for a tai-
lored therapeutic strategy.
Objective: We sought to compare the prognostic value of three ACS risk scores (RS) and
their ability to predict benefit from myocardial revascularization performed during the ini-
tial hospitalization.
Methods: We studied 460 consecutive patients admitted to our CCU with an ACS. For
each patient, the TIMI, PURSUIT and GRACE RS were calculated. Their prognostic
value was evaluated by the combined incidence of death (D) or myocardial infarction (MI)
at 1 year. The best cut-off value for each RS, was used to assess the impact of myocar-
dial revascularization on D or MI at 1 year.
Results: D or MI at 1 year was 15.4% (32 D/ 49 MI). The best predictive accuracy for D or
Demographics 
M (1123) W (601) P value
Age yrs 62 67 <0.0001
Heart Failure % 17 25 <0.0001
BP systolic mmHg 138 142 0.004
Tobacco % 70 50 <0.0001
Cardiac Enzymes + 72 71 0.44
PCI or CABG % 52 41 <0.0001
PCI % 45 33 <0.0001
CABG % 7.3 8.2 0.49
Angiography %
Normal/mild CAD 31 43 <0.0001
1 vessel 18 16 0.20
2 vessel 16 16 0.88
3 vessel 22 18 0.04
Left main 3.3 2.2 0.18
30-day outcomes Patients without 
Holter Ischemia
(N=592)
Patients with 
Holter Ischemia
(N=261)
Odds Ratio [OR] 
(95% CI)
P value
Death/Myocardial 
Infarction (MI)
3.4% 10.7% 3.4 (1.9-6.2) <0.001
Death 1.0% 5.0% 5.1 (1.9-13.6) 0.001
Caucasian (n=832) African-American (n=739) p-value 
Hypertension 50% 71% <0.001
Diabetes 22% 30% 0.0007
Smoking 61% 61% 0.86
Hyperlipidemia 36% 25% <0.0001
Lipid Lowering Drugs 16% 13% 0.19
Aspirin 21% 19% 0.33
Beta-Blockers 13% 13% 0.19
ACE inhibitors 18% 22% 0.03
Catheterization 61% 43% <0.0001
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MI at 1 year was obtained by the GRACE RS but the performance of the PURSUIT and
TIMI RS was good. We found a statistically significant interaction between the risk strati-
fied by the best cut-off value for the GRACE and PURSUIT RS and myocardial revascu-
larization, with a prognostic benefit for the higher risk patients.
Conclusions: The risk scores studied demonstrated a good predictive accuracy for D or
MI at 1 year and allowed the identification of high risk subsets of patients that most bene-
fit from myocardial revascularization performed during the initial hospital stay. 
1098-78 Low Hemoglobin Predicts Worse Clinical Outcomes in 
Acute Coronary Syndromes
Marc S. Sabatine, David A. Morrow, Robert P. Giugliano, Sabina A. Murphy, Carolyn H. 
McCabe, C. Michael Gibson, Christopher P. Cannon, Elliott M. Antman, Eugene 
Braunwald, for the TIMI Study Group, Brigham and Women's Hospital, Boston, MA
Background: In acute coronary syndromes (ACS), anemia has the potential to worsen
myocardial ischemia by further compromising oxygen delivery. We sought to determine
the impact of anemia on clinical outcomes in a broad cohort of patients with ACS.
Methods: Data from 22,333 patients with STEMI and 17,547 patients with UA/NSTEMI
from the pooled TIMI trial databases were analyzed. Baseline hemoglobin (Hgb) levels
were categorized in 1 g/dl increments. Multivariable logistic regression was used to
adjust for age, sex, hypertension, diabetes, smoking, renal insufficiency, prior MI, prior
CHF, prior ASA, prior CABG, and index revascularization.
Results: Lower baseline Hgb levels were associated with greater evidence of acute myo-
cardial injury in both STEMI (higher rates of Killip class II-IV and LBBB, p<0.001 for each)
and UA/NSTEMI (higher rates of ST deviation and higher peak troponin, p<0.001 for
each). In STEMI, patients with lower baseline Hgb levels had higher mortality at 30 days
(p<0.001) and in UA/NSTEMI they had higher rates of death, MI, or recurrent ischemia
(p<0.001). These associations remained significant even after adjusting for potential con-
founders and the adjusted odds ratios and 95% confidence intervals are presented in the
Figure.
Conclusion: Low Hgb on admission is independently associated with worse outcomes in
patients with ACS. These findings suggest that efforts to raise Hgb may be beneficial in
this setting. 
1098-79 Renal Function Predicts Outcomes in Acute Coronary 
Syndromes: Insights From the CURE Trial
Matyas Keltai, Marcello Tonelli, Johannes F. Mann, Basil Lewis, Steven Hawken, Shamir 
Mehta, Nasser Lakkis, Salim Yusuf, Hungarian Institute of Cardiology, Budapest, 
Hungary, McMaster University, Hamilton, ON, Canada
Background: Chronic renal insufficiency (CRI) is associated with increased mortality in
coronary artery disease. The aim of this study was to assess the relationship between
various degree of renal insufficiency and prognosis in patients (pts) with acute coronary
syndromes (ACS) Additionally we assessed if benefit of clopidogrel treatment is modified
in pts with CRI.
Methods: In the CURE trial 12.253 patients (97.5 %) had a baseline serum creatinine
measurement at enrollment. From this measurement the glomerular filtration rate (GFR)
was estimated using the MDRD equation, and the outcomes of patients with and without
CRI were compared.
Results: 3262 patients (26.2 %) had a GFR < 60 ml/min, corresponding to at least mod-
erate CRI. Patients with CRI were significantly older (70.3 +9.5, versus 62.0 +11.0).
Among patients with CRI there were more females (53.8, versus 32.8 % in the group
without CRI), and significantly more hypertensives (70, versus 54.9 %), diabetics (29,
versus 20.3 %) and more patients with previous myocardial infarction (39.8, versus 29.5
%). Major vascular events (cardiovascular death/myocardial infarction/stroke) occured
more frequently in patients with CRI (GFR>60 - 8.6 %; GFR 30.1-60 - 14.4 %;GFR 0-30
25.5 %). A significant gradient was present in all secondary outcome measures relative
to GFR. The beneficial effect of adding clopidogrel to standard treatment of ACS was
similar and statistically significant in pts below and above the median value of GFR, with
no evidence of statistical heterogeneity (RR 0.83; 95 % CI:0.72-0.95, versus 0.73; 95 %
CI: 0.61-0.87). The risk of major/life-threatening bleeding was increased in patients with
CRI in the CURE trial population (2.1 versus 1.0 %), this risk only moderately increased
by adding clopidogrel, and the hazard ratio was similar in patients with CRI (HR 1.5 +
1.16 - 1.92) and without CRI (HR 1.14+ 0.83 - 1.59).
Conclusion: CRI carries a poor prognosis in pts with non ST elevation ACS. Adding clo-
pidogrel to standard treatment of ACS was safe and resulted in a decreased incidence of
major cardiovascular outcomes in patients with and without CRI .
1098-80 High-Normal Creatinine: An Underappreciated Predictor 
of Poor Outcomes in Chest Pain Patients
Charles A. Henrikson, David E. Bush, Eric E. Howell, Nisha Chandra-Strobos, Johns 
Hopkins Medical Institutions, Baltimore, MD
Background: Patients with renal insufficiency have poor outcomes following acute myo-
cardial infarction (MI) or unstable angina. However, little investigation has focused on the
impact of high-normal creatinine on clinical outcomes.
Methods: We prospectively followed 459 patients with ongoing chest pain admitted to the
hospital with suspected myocardial ischemia. Patients with elevated creatinine (>=1.4
mg/dL, n=58) were excluded.
Results: Patients with high-normal creatinine (1.0-1.3 mg/dL, n=129), compared to those
with low-normal creatinine (<1.0 mg/dL, n=272), tended to be male (66% v. 36%), hyper-
tensive (66% v. 52%), and older (62 +/-16 v. 55 +/- 15 yrs (mean+/-SD)) (all p<0.05), but
the rates of diabetes mellitus (24% v. 20%), high cholesterol (36% v. 44%), and MI at pre-
sentation (16% v. 10%) were similar (all p=NS). Among patients with high-normal creati-
nine, 22% (unadjusted) suffered a subsequent MI, revascularization, or death by 120
days. This compares to 13% in patients with low-normal creatinine (p<0.05). The Kaplan-
Meier curve, adjusted for baseline differences between the two groups, confirmed a
higher rate of subsequent MI, revascularization, or death in the high-normal creatinine
group as compared to the low-normal creatinine group, mainly attributable to an increase
in early events (p<0.05).
Conclusion: These data identify high-normal creatinine as an independent, albeit under-
appreciated, risk factor for poor outcomes in patients with suspected myocardial
ischemia.
1098-81 Which White Blood Cell Compartments Predict 
Increased Cardiovascular Risk?
Jerry M. John, Jeffrey L. Anderson, Benjamin D. Horne, Tami L. Bair, Kurt R. Jensen, 
Heath U. Jones, Dale G. Renlund, Joseph B. Muhlestein, LDS Hospital, Salt Lake City, 
UT, University of Utah, Salt Lake City, UT
Background: Epidemiological observations have associated an elevated white blood cell
(WBC) count with the development of cardiovascular disease, but which leukocyte com-
partments carry this risk is uncertain.
Methods: Patients entered into the Intermountain Heart Collaborative Study Registry
between 1994–2001 who had angiographic assessment of coronary artery disease
(CAD), a baseline total and differential WBC count, and long-term follow-up for death or
nonfatal myocardial infarction (MI) were studied. Patients (pt) with acute MI were
excluded from primary analyses. The predictive value for D/MI of total WBC, neutrophil
(N), lymphocyte (L), monocyte (M) counts, and N/L ratio was assessed using Cox regres-
sions.
Results: 3227 pt were studied. Mean age was 64; 62% were male; 53%, hypertensive;
45%, hyperlipidemic; 17%, smokers; 20%, diabetic. Time to event (N=478, 14.8%) or last
follow-up averaged 3.5 years. WBC total and compartment counts were non-normally
distributed. In univariate analysis, an increased hazard (HR) ratio was associated with
fourth (vs. first) quartile (Q) total WBC (1.4, p<0.01), N (2.0, p<0.001), L (0.41, p<0.001),
M (1.4, p<0.01), and N/L (2.7, p<<0.001) counts. In multivariable modeling (backward
conditional stepwise regression), entering standard risk factors, presentation, and CAD
severity, WBC (HR 1.4, p=0.01) and M (HR 1.3, p<0.02) were weaker and N (HR 1.8,
p<0.001), L (HR 0.51, p<0.001), and N/L (HR 2.2, p<0.001) were stronger independent
predictors of death/MI. When WBC variables were entered together, N/L was retained as
an independent predictor (HR 2.2, CI 1.7-2.9, p<<0.001), together with age, diabetes,
presentation, CAD severity, family history, and M (model chi-square 190). Risk associa-
tions persisted in analyses restricted to CAD pt or including acute MI pt.
Conclusions: Total WBC count is confirmed to be an independent predictor of D/MI in
